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OBJECTIVE: Cross-sectional studies have been conducted to evaluate the adequacy of prophylaxis for venous
thromboembolism. However, these studies often evaluate prophylaxis on the data collection day, without
analysing the prophylactic dose or duration and without reference to inappropriate use in patients without
risk. A prospective, observational study was performed to assess the adequacy of prophylaxis in a general
medicine ward of a university hospital.
METHOD: In the analysis, the use of the proper prophylactic dose at the correct time, the use in patients with
contraindications, and the misuse in patients without risk of venous thromboembolism were considered.
RESULTS: A total of 245 patients were evaluated. Of these patients, 104 (42.4%) were considered to be at risk,
and 82.7% either received adequate prophylaxis (i.e., the correct dose at the right time) or did not receive
prophylaxis because it was contraindicated. Among the 141 patients who were not at risk, 81 (57.4%)
incorrectly received prophylaxis, the majority (61/81) of whom presented with risk factors but did not
demonstrate reduced mobility. Among the entire group, only 59.6% of patients were properly treated.
CONCLUSIONS: The evaluation of prophylaxis adequacy should consider not only whether the correct dose is
administered at the correct time but also whether it is used in patients with contraindications and whether it is
inappropriately administered to patients who are not at risk.
KEYWORDS: Deep Vein Thrombosis; Guidelines; Inpatients; Pulmonary Embolism; Prophylaxis.
Alckmin CA, Garcia MD, Bricola SA, Martins MA, Lichtenstein A, Paiva EF. Venous thromboembolism risk assessment in hospitalised patients: A
new proposal. Clinics. 2013;68(11):1416-1420.
Received for publication on May 13, 2013; First review completed on May 30, 2013; Accepted for publication on May 30, 2013
E-mail: paiva.edison@gmail.com
Tel.: 55 11 2661-7690
& INTRODUCTION
Although venous thromboembolism (VTE) is the main
preventable cause of death in hospitalised patients (1,2),
VTE prophylaxis is still not routinely administered in most
hospitals (3-6). There are numerous barriers to prophylaxis
use, especially the natural resistance to change, fear of side
effects, lack of effective institutional policies, and even lack
of knowledge regarding the guidelines or difficulties in
remembering the recommendations (7). Therefore, having a
simple tool to aid in risk assessment and prophylaxis
prescription is essential. However, various proposals from
international societies indicate the lack of a universally
accepted tool (8-11).
Studies assessing the adequacy of VTE prophylaxis are
usually limited to an analysis of the number of patients at
risk and the number who received prophylaxis (mechanical
or drug) (3-6). Moreover, cross-sectional studies with data
collected on a single day are common; however, these
studies do not allow for an assessment of the adequacy of an
anticoagulant dose or prophylaxis duration (4-6). In addi-
tion, patients not at risk for a VTE who received improper
prophylaxis are not typically described in these studies (4-
6).
The primary objective of this study was to evaluate the
adequacy of VTE prophylaxis in a general medical ward
and to present the results in a systematic manner, including
the results of patients who were and were not at risk and
details regarding why the use of prophylaxis was correct or
incorrect.
& METHODS
This prospective, observational study was conducted
from October to December 2010 in a general practice ward
of the Hospital das Clı´nicas da Faculdade de Medicina da
Universidade de Sa˜o Paulo, which is a university hospital
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and the biggest quaternary public hospital in Brazil. The
personnel in the ward are divided into four groups, each
consisting of second-year internal medicine residents, fifth-
year medical students, and assistant teachers who regularly
guide the team. Prescriptions are prepared by the second-
year residents and checked by the assistant teachers during
rounds. At the time of the study, there was no institutional
protocol for or systematic training in VTE prophylaxis;
therefore, the procedures varied according to the experience
of the doctors working during that period. The study was
approved by the local ethical committee, and because this
study was observational in nature, informed consent was
not required.
Assessment of VTE risk
The algorithm from the Brazilian Guidelines for VTE
Prophylaxis in Hospitalised Patients was used to assess VTE
risk (Figure 1). According to this algorithm, the patient is
initially evaluated for reduced mobility and age .40 years.
Reduced mobility is defined as an acute loss of mobility
secondary to the cause of hospital admission that requires
the patient to remain primarily lying down or sitting at the
bedside for an estimated duration of at least 3 days. To be
considered at risk for VTE, patients must be at least 40 years
of age; however, the doctor should consider the risk for each
individual with significant risk factors for VTE, even if the
patient is younger than 40 years of age. If the initial criteria
are not met, the patient is not considered to be at risk and
should have his or her health condition re-evaluated at least
every 2 days. If the initial criteria are met, the presence of
an additional risk factor related to VTE development is
assessed. If there is at least one additional risk factor, the
patient is considered to be at risk (Figure 1). If the patient is
considered to be at risk for VTE, the contraindications for
chemoprophylaxis are assessed. If the contraindication is
absolute or if the doctor considers the risk of bleeding to be
greater than the risk of thrombosis, the patient should
receive mechanical prophylaxis; otherwise, chemoprophy-
laxis is indicated. The protocol was completed for each
patient, and the data were extracted from the patient
records during admission. The doctors responsible for
patient care were not aware of the collected data.
Adequacy of prophylaxis
According to the Brazilian Guidelines, VTE prophylaxis
for medical patients should be performed with unfractio-
nated heparin (UFH) or low-molecular-weight heparin at
high prophylactic doses (8). At the hospital utilised for this
Figure 1 - Algorithm from the Brazilian Guidelines for VTE Prophylaxis in Hospitalised Patients.
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study, only UFH and enoxaparin were available; the doses
considered suitable were 5,000 U SC every 8 hours and
40 mg SC every 24 hours, respectively. For patients with a
creatinine clearance of less than 30 mL/min, UFH 5000 U
SC every 12 hours or enoxaparin 20 mg SC every 24 hours
was considered to be appropriate (8). Prophylaxis was
considered incorrect when the doses differed from these
standards, when chemoprophylaxis was used in patients
with an absolute contraindication, or when prophylaxis was
not administered for 3 or more days during any period of
hospitalisation.
The adequacy of prophylaxis and the development of
deep vein thrombosis (DVT) or symptomatic pulmonary
embolism (PE) were evaluated daily in each patient during
the hospitalisation. Phone calls were performed at 30 and 90
days after discharge to identify VTE occurrence or death
secondary to PE.
Statistical analyses
Because this study was observational with the primary
objective of assessing the adequacy of prophylaxis according
to the Brazilian Guidelines for Prevention of VTE, statistical
analyses were not required. The patients who developed
symptomatic VTE were identified. However, the study was
not designed to compare rate of VTE development between
patients who did or did not receive prophylaxis.
& RESULTS
During the study, 248 patients were admitted to the
hospital; 3 were admitted with existing thrombosis and
were excluded from the analysis. Of the 245 remaining
patients, 132 (53.9%) were female. The patient ages ranged
from 13 to 91 years; the average age was 54.3¡19.2 years;
and the average hospitalisation time was 18.8¡16.9 days
(Table 1). A total of 104 (42.4%) of the 245 patients were
considered to be at risk for VTE according to the Brazilian
Guidelines. Most of the at-risk patients were female (57.7%),
with an average age of 61.3¡15.3 years and an average
hospitalisation time of 22.3¡18.4 days. In this group, the
patients had an average of 2.9¡1.2 risk factors for VTE;
56.8% had 3 or more risk factors, and 8.7% had 5 or 6
additional risk factors (Table 1). The risk factors found most
often were as follows: age 55 years or older (26.6%),
infection (11.3%), cancer (11.0%), tobacco use (10.0%), heart
failure (functional class III or IV; 7.3%), severe respiratory
disease (6.0%), and nephrotic syndrome (5.3%; Table 2).
The analysis of prophylaxis adequacy showed that 86 of
the 104 patients (82.7%) at risk for VTE were treated
properly [i.e., they had no contraindications and received
the correct dose of prophylactic drug (77/104; 74.0%) or had
an absolute contraindication and were not given chemopro-
phylaxis (9/104; 8.7%; Table 3)]. Eighteen (17.3%) patients at
risk for VTE did not receive the correct prophylaxis, either
because heparin was not used in the absence of contra-
indications (14/104; 13.5%) or because chemoprophylaxis
was used in the presence of an absolute contraindication (4/
104; 3.8%; Table 3).
Among the 141 patients with no risk factors for VTE, the
correct prophylaxis was used in 60 (42.6%) cases (Table 3).
However, in 81 (57.4%) patients, chemoprophylaxis was
used improperly. These patients were not considered to be
at risk for VTE for the following reasons: no reduced
mobility (68/141; 48.2%), no risk factors (6/141; 4.3%), or no
reduced mobility or additional risk factors for VTE (7/141;
5.0%; Table 3). Considering all 245 patients, the prophylaxis
was correct in 146 patients (59.6%) and incorrect in 99
(40.4%).
In 3 of the 245 patients (1.2%), VTE was detected at some
point during the hospitalisation period or after discharge.
Below is a brief description of each of these cases.
Patient 1 was a 57-year-old female with inactive systemic
lupus erythematous and a history of smoking. She was
admitted with reduced mobility due to asthenia and
weakness, which were attributed to depression at the end
of her 10-day hospitalisation. Twenty days after discharge,
she passed away from a PE diagnosed at another facility; an
autopsy was not performed. Her risk factors included age
$55 years and smoking history. During her hospitalisation,
Table 1 - Characteristics of the hospitalised patients according to VTE risk.
Characteristics Total With VTE Risk Without VTE Risk
Number of patients, N (%) 245 (100.0%) 104 (42.4) 141 (57.6)
Females, N (%) 132 (53.9%) 60 (57.7) 72 (51.1)
Males, N (%) 113 (46.1) 44 (42.3) 69 (48.9)
Mean age in years (SD) 54.3 (19.2) 61.3 (15.3) 49.1 (20.2)
Mean days of hospitalisation (SD) 18.8 (16.9) 22.3 (18.4) 16.0 (15.2)
Mean number of RFs for VTE (SD) 2.2 (1.4) 2.9 (1.2) 1.7 (1.2)
3 or more RFs (%) 40.0 56.8 27.7
5 or 6 RFs (%) 3.7 8.7 0.0
VTE, venous thromboembolism; SD, standard deviation; RFs, risk factors.
Table 2 - Risk factors exhibited by patients considered to
be at risk for VTE listed in descending order of frequency.
Risk factor N %




Heart failure (functional class III or IV) 22 7.3
Severe respiratory disease 18 6.0
Nephrotic syndrome 16 5.3
Hospitalisation in the intensive care unit 15 5.0
Varicose veins and venous insufficiency 13 4.3
Previous or family history of VTE 9 3.0
Ischemic stroke 8 2.7
Central venous catheterisation 8 2.7
Acute myocardial infarction 4 1.3
Paresis or paralysis of the lower limbs 4 1.3
Active rheumatic disease 3 1.0
Chemotherapy or hormone therapy 2 0.7
Obesity 1 0.3
Arterial insufficiency 1 0.3
VTE, venous thromboembolism.
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she was considered to be at risk for VTE and received
prophylaxis with UFH 5000 U 3 times a day.
Patient 2 was a 62-year-old male admitted for lower limb
paresis secondary to vitamin B12 deficiency. He was
considered to be at risk for VTE, received prophylaxis with
UFH 5000 U 3 times a day for 7 days, was maintained
without prophylaxis for 5 consecutive days, and then
received prophylaxis with enoxaparin 40 mg daily for 5
days before being diagnosed with a DVT. His risk factors
included age $55 years and lower limbs paresis.
Patient 3 was a 19-year-old female with mental retarda-
tion. She was bedridden at home for 6 months with a history
of extensive weight loss due to pulmonary tuberculosis that
was diagnosed only on admission. In addition to tubercu-
losis, venous thrombosis of the subclavian and lower limbs
was detected after admission, and whether these throm-
boses developed before or after admission was unclear. She
did not meet the risk criteria for VTE due to being quite
young and having chronically decreased mobility. She was
adopted, so obtaining data regarding familial thrombosis
was not possible. No investigation regarding the presence of
thrombophilia was performed.
& DISCUSSION
A total of 42.4% of the medical patients were at risk for
VTE. This rate is similar to the value found in the ENDORSE
study, which evaluated 68,183 patients admitted from 32
countries and found that 41.5% of the hospitalised medical
patients were at risk for VTE (4).
The average length of hospitalisation in the present study
was high (22.3 days), and the patients had multiple
additional risk factors for VTE (an average of 2.9, and
56.8% had 3 or more risk factors). The rate of symptomatic
events detected in the present study was 1.2%, which is
similar to the values of 1.0 to 1.5% in the placebo groups
from studies of prophylaxis in hospitalised medical patients
(12,13).
Of the patients at risk for VTE, 82.7% correctly received
prophylaxis. Compared with other studies, this rate is
significantly high. In the ENDORSE study mentioned above,
which evaluated prophylaxis in 32 countries, the rates of
prophylaxis use were quite heterogeneous, with an average
rate of 50%, and only 2 countries reached adequacy rates
close to 80% (Germany and Switzerland). Notably, the
criteria used in ENDORSE were not as strict; prophylaxis
was appropriate when the patient received any antic-
oagulant, regardless of the dose or duration of treatment
(4). The high rate of adequate prophylaxis in patients at risk
may be explained by the fact that the study was conducted
in a university hospital, where the medical staff are
concerned about patient safety, even though no institutional
protocol for VTE prophylaxis was available at that time and
the doctors had not received specific training for VTE
prophylaxis. However, it is possible that this same concern
resulted in excessive prophylaxis use in patients who were
not at risk for VTE. Of the 141 patients who were not at risk,
81 (57.4%) incorrectly received prophylaxis, and most (68/
81) were patients without reduced mobility.
Prophylaxis was correctly administered to 59.6% of the
patients included in this study. We believe that this statistic
is the best way to assess adequate prophylaxis administra-
tion, although this type of analysis is not commonly
reported. In fact, in our review, we did not identify any
study that included a similar analysis.
In conclusion, in a university hospital with patients of
high complexity, 42.4% of the hospitalised patients were at
risk for VTE, and the majority (82.7%) received the proper
prophylaxis. However, more than half (57.4%) of the
patients who were not at risk also received prophylaxis,
which means that only 59.6% of the patients were properly
treated. The analysis of adequate use of prophylaxis should
consider not only the correct use of prophylaxis in patients
at risk but also inadvertent use in patients who are not at
risk.
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Table 3 - The adequacy of VTE prophylaxis according to the Brazilian Guidelines.
Characteristic Number %
At risk for VTE 104 100.0
Correct prophylaxis 86 82.7
Pharmacological prophylaxis, no absolute contraindication and administered at the correct dose 77 74.0
With absolute contraindication and no pharmacological prophylaxis 9 8.7
Incorrect prophylaxis 18 17.3
Not performed and no contraindication was present 14 13.5
Incorrect dose 0 0.0
Performed despite an absolute contraindication 4 3.8
Not at risk for VTE 141 100.0
Correct prophylaxis (did not receive prophylaxis) 60 42.6
Incorrect prophylaxis (received prophylaxis) 81 57.4
No reduced mobility 68 48.2
Reduced mobility, but no risk factors 6 4.3
No reduced mobility and no risk factors 7 5.0
All patients 245 100.0
Correct prophylaxis 146 59.6
Incorrect prophylaxis 99 40.4
VTE, venous thromboembolism.
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